Why the study?
Does angiotensin receptor-neprilysin inhibition (ARNI) improve management in patients with hypertension and heart failure?
Does angiotensin receptor-neprilysin inhibition (ARNI) improve management in patients with hypertension and heart failure?
Answers are grounded in this paper and cite their sources.
ARNI represents a novel therapeutic concept for the management of hypertension and heart failure.
The Renin-Angiotensin–Aldosterone System (RAAS) is central to blood pressure (BP) control, and chronic activation of the system, as occurs in some hypertensive patients, leads to damage of target o...
No takes yet. Share an insight, caveat, or question.
Kjeldsen et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: